Fri Sep 20 12:16:17 UTC 2024: ## Notable Labs Downgraded by JMP Securities: Focus Shifts from “Outperform” to “Market Perform”
**New York, NY – September 20, 2024** – Notable Labs (NASDAQ: NTBL), a clinical-stage platform therapeutics company specializing in predictive precision medicines for cancer patients, has been downgraded by JMP Securities from an “outperform” rating to a “market perform” rating. The decision, announced in a research report issued Friday, reflects the analysts’ revised outlook on the company’s prospects.
Notable Labs’ stock opened at $0.48 on Friday, with a 52-week low of $0.45 and a 52-week high of $10.08. The company’s recent quarterly earnings report, released on August 14th, showed a loss of $0.55 per share. Analysts anticipate a full-year EPS of -0.75.
Notable Labs’ proprietary Predictive Precision Medicines Platform (PPMP) is designed to simulate cancer treatment and predict patient response to actual therapy.
JMP Securities’ decision to downgrade Notable Labs suggests a cautious approach to the company’s future performance. The market’s reaction to this news, however, remains to be seen.
First Piper 